Karuna Pays US$15 M Upfront for Goldfinch Bio’s TRPC4/5 Inhibitors

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)

Published: 24 Feb-2023

DOI: 10.3833/pdr.v2023.i2.2767     ISSN: 1756-7874

Section: Licensing



In an attempt to bolster its neurology pipeline, Karuna Therapeutics has agreed to pay Goldfinch Bio US$15 M upfront and up to US$520 M in potential milestone payments for the latter’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details